An angiogenesis inhibitor: TNP-470;Un inhibiteur de l'angiogenese: Le TNP-470

Bulletin du Cancer

Volumn 87, Issue 6, 2000, Pages 449-454

  Bailly, Christian ^a   Lansiaux, Amélie ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE; ANTINEOPLASTIC ANTIBIOTIC; CYCLOHEXANE DERIVATIVE; O-(CHLOROACETYLCARBAMOYL)FUMAGILLOL; SESQUITERPENE;

ANTINEOPLASTIC ACTIVITY; CONTAMINATION; ENDOTHELIUM CELL; ENZYME MODIFICATION; GROWTH INHIBITION; HYDROLYSIS; NEOVASCULARIZATION (PATHOLOGY); REVIEW; TUMOR GROWTH; ANIMAL; ARTICLE; CHEMISTRY; CLINICAL TRIAL; DRUG SCREENING; EXPERIMENTAL MELANOMA; FEMALE; GLIOBLASTOMA; HUMAN; MOUSE; RAT; UTERINE CERVIX TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CLINICAL TRIALS; CYCLOHEXANES; FEMALE; GLIOBLASTOMA; HUMANS; MELANOMA, EXPERIMENTAL; MICE; RATS; SESQUITERPENES; TUMOR STEM CELL ASSAY; UTERINE CERVICAL NEOPLASMS;

EID: 0034198739     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. 1. Folkman J. Tumor angiogenesis : therapeutic implications. N Engl J Med 1971 ; 285 : 1182-6.
2. 2. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990 ; 348 : 555-7.
3. 3. Killough J, Magill G, Smith R. The treatment of amoebiasis with fumagillin. Science 1952 ; 115 : 71-2.
4. 4. Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D, et al. Potent anti-angiogenic action of AGM-1470 : comparison to the fumagillin parent. Biochem Biophys Res Commun 1991 ; 174 : 1070-6.
5. 5. Marui S, Kishimoto S. Chemical modification of fumagillin. I. 6-O-acyl, 6-O-sulfonyl, 6-O-alkyl, and 6-O-(N-substituted-carbamoyl)fumagillols. Chem Pharm Bull 1992 ; 40 : 96-101.
6. 6. Marui S, Kishimoto S. Chemical modification of fumagillin. II. 6-amino-6-deoxyfumagillol and its derivatives. Chem Pharm Bull 1992; 40: 575-9.
7. 7. Turk BE, Su Z, Liu JO. Synthetic analogues of TNP-470 and ovalicin reveal a common molecular basis for inhibition of angiogenesis and immunosuppression. Bioorg Med Chem 1998 ; 6 : 1163-9.
8. 8. Sin N, Meng L, Wang MQW, Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP2. Proc Natl Acad Sci USA 1997 ; 94 : 6099-103.
9. 9. Abe J, Zhou W, Takuwa N, Taguchi J, Kurokawa K, Kumada M, et al. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylatlon of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 1994 ; 54 : 3407-12.
10. 10. Turk BE, Griffith EC, Wolf S, Biemann K, Chang YH, Liu JO. Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. Chem Biol 1999 ; 6 : 823-33.
11. 11. Griffith EC, Su Z, Turk BE, Chen S, Chang YW, Wu Z, et al. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol 1997 ; 4 : 461-71.
12. 12. Wang J, Quan N, Henkin J. Human endothelial cells are exceptionnaly sensitive to loss of methionine aminopeptidase-2 (Met AP2). Proc Am Assoc Cancer Res 1998 ; 39 : 98.
13. 13. Griffith EC, Su Z, Niwayama S, Ramsay CA, Chang YH, Liu JO. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc Natl Acad Sci USA 1998 ; 95 : 15183-8.
14. 14. Liu S, Widom J, Kemp CW, Crews CM, Clardy J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 1998 ; 282 : 1324-7.
15. 15. Placidi L, Cretton-Scott E, de Sousa G, Rahmani R, Placidi M, Sommadossi JP. Disposition and metabolism of the angiogenic moderator O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) in human hepatocytes and tissue microsomes. Cancer Res 1995 ; 55 : 3036-42.
16. 16. Figg WD, Pluda JM, Lush RM, Saville MW, Wyvill K, Reed E, et al. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 1997 ; 17 : 91-7.
17. 17. Kamei S, Okada H, Inoue Y, Yoshioka T, Ogawa Y, Toguchi H. Antitumor effects of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. J Pharmacol Exp Ther 1993 ; 264 : 469-74.
18. 18. Yanai S, Okada H, Saito K, Kuge Y, Misaki M, Ogawa Y, et al. Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma. Pharm Res 1995 ; 12 : 653-7.
19. 19. Kanai T, Konno H, Tanaka T, Baba S. Inhibition of metastases of human stomach cancer constructed using orthotopic implantation in nude mouse by angiogenesis inhibitor TNP-470. Proc Am Ass Cancer Res 1996 ; 37 : 392.
20. 20. Sasaki A, Alcalde RE, Nishiyama A, Lim DD, Mese H, Akedo H, et al. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption. Cancer Res 1998 ; 58 : 462-7.
21. 21. Takamiya Y, Brem H, Ojeifo J, Mineta T, Martuza RL. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 1994 ; 34 : 869-75.
22. 22. Tanaka T, Konno H, Matsuda I, Nakamura S, Baba S. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res 1995 ; 55 : 836-9.
23. 23. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470 ; AGM-1470). Cancer Res 1993 ; 53 : 4262-7.
24. 24. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 1993 ; 53 : 5233-6.
25. 25. Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 1993 ; 53 : 2566-70.
26. 26. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999 ; 284 : 808-12.
27. 27. Hori K, Li HC, Saito S, Sato Y. Increased growth and incidence of lymph node metastases due to the angiogenesis inhibitor AGM-1470. Br J Cancer 1997 ; 75 : 1730-4.
28. 28. Klauber N, Rohan RM, Flynn E, D'Amato RJ. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nature Med 1997 ; 3 : 443-6.
29. 29. Kato T, Sato K, Kakinuma H, Matsuda Y. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 1994 ; 54 : 5143-7.
30. 30. Teicher BA, Holden SA, Ara G, Sotomayor EA, Huang ZD, Chen YN, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994 ; 57 : 920-5.
31. 31. Herbst RS, Teicher BA. Paclitaxel/carboplatine administration along with angiogenic therapy in non-small cell lung and breast carcinoma models. Ann Oncol 1998 ; 9 : S78.
32. 32. Konno H, Tanaka T, Matsuda I, Kanai T, Maruo Y, Nishino N, et al. Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and mitomycin C on the growth and liver metastasis of human colon cancer. Int J Cancer 1995 ; 61 : 268-71.
33. 33. Castronovo V, Belotti D. TNP-470 (AGM-1470) : mechanisms of action and early clinical development. Eur J Cancer 1996 ; 32A : 2520-7.
34. 34. Konno H. Antitumor effect of the angiogenesis inhibitor TNP-470 on human digestive organ malignancy. Cancer Chemother Pharmacol 1999 ; 43 : S85-9.
35. 35. Gleich LL, Biddinger PW, Paveli ZP, Gluckman JL. Tumor angiogenesis in T1 oral cavity squamous cell carcinoma : role in predicting tumor aggressiveness. Head and Neck 1996 ; 18 : 343-6.
36. 36. Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G, et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 1997 ; 151 : 1417-23.
37. 37. Gleich LL, Zimmerman N, Lixin Wang YO, Gluckman JL. Angiogenic inhibition for the treatment of head and neck cancer. Anticancer Res 1998 ; 18 : 2607-10.
38. 38. Dezube BJ, Von Roenn JH, Holden-Wiltse J, Cheung TW, Remick SC, Cooley TP, et al. Fumagillin analog in the treatment of Kaposi's sarcoma : a phase I Aids Clinical Trial Group study. J Clin Oncol 1998 ; 16: 1444-9.
39. 39. Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, et al. A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999 ; 5 : 1989-95.
40. 40. Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termrungruanglert W, et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 1997 ; 3 : 1501-5.
41. 41. Kudelka AP, Verschraegen CF, Loyer E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N Engl J Med 1998 ; 338 : 991-2.
42. 42. Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 1999 ; 17 : 2541.
43. 43. Beckner ME. Factors promoting tumor angiogenesis. Cancer Invest 1999; 17 : 594-623.
44. 44. Vandenbunder B. Angiogenesis update. Bull Cancer 1999 ; 86 : 29-36.
45. 45. Shishido T, Yasoshima T, Denno R, Mukaiya M, Sato N, Hirata K. Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin. Jpn J Cancer Res 1998 ; 89 : 963-9.